Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bio-Rad Laboratories

Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the Life Sciences and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, and test kits. The company was founded by David S. Schwartz and Alice N. Schwartz in 1952 and is headquartered in Hercules, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bio-Rad Laboratories reports robust earnings, eyes growth through new products

Bio-Rad Laboratories showcased strong financial performance, operational improvements, and strategic initiatives during the Q4 2022 earnings call. Despite challenges like supply chain disruptions and margin impacts, the company remains optimistic about its growth prospects and commitment to long-term targets.

Bio-Rad reports resilient Q1 performance amidst challenges and opportunities

Bio-Rad Laboratories navigated challenges in Q1 2023 to achieve core sales growth and solid non-GAAP net income, with a revised 2023 outlook projecting 4.5% revenue growth.
The impact of Russian sanctions and margin improvement plans were key discussion points, alongside the company's focus on expense management and operational transformation.
With a strategic approach to growth, strong performance in key business segments, and a focus on operational efficiency, Bio-Rad aims to capitalize on opportunities for expansion and resilience.

Bio-Rad reports Q2 earnings decline, eyes ddPCR growth opportunities

Bio-Rad Laboratories faced challenges in BioPharma but showed strengths in Clinical Diagnostics and Life Science segments.
Despite a decline in net sales, the company reported strong demand for ddPCR and authorized a new share repurchase program.
Anticipated challenges in BioPharma and China may impact revenue growth, but opportunities exist in expanding ddPCR sales and cost-saving measures.
The company maintains a strong cash position, views its valuation favorably, and plans to participate in upcoming healthcare conferences.

Bio-Rad Labs faces Q3 challenges, eyes ddPCR market growth

Bio-Rad Laboratories faced challenges in Q3 2023 due to biopharma segment issues and economic constraints in China, impacting revenue and forecasting.
Despite weaknesses, the company saw growth in Clinical Diagnostics revenue and remains focused on operational transformation and strategy execution.
Analysts raised concerns about market dynamics and share losses, while Bio-Rad plans to address challenges and capitalize on opportunities in the ddPCR market.
The company anticipates a strong Q4 to offset Q3 challenges and is prepared for potential macroeconomic impacts on biotechnology spending.

Bio-Rad Labs reports Q4 revenue decline, eyes growth opportunities

Bio-Rad Laboratories navigated challenges in Q4 2023, with revenue declines but operational resilience in key segments.
The company faces headwinds in the China market but sees opportunities in new product launches and market recovery.
Financial stability is evident with strong cash reserves, while strategic adjustments are needed to drive future growth.
Guidance for 2024 hints at a potential turnaround, with a focus on operational efficiency and revenue expansion.

Bio-Rad Laboratories reports mixed Q1 performance, maintains outlook optimism

Bio-Rad Laboratories' Q1 2024 earnings call highlighted a mixed performance with declines in Life Science sales but growth in Clinical Diagnostics. Despite challenges in certain segments, the company maintains its full-year outlook and is optimistic about long-term growth strategies and market trends.

Bio-Rad Laboratories reports solid Q2 performance amidst global spending constraints

Bio-Rad Laboratories had a solid quarter but revised full-year outlook due to global spending constraints.
Operational improvements and successful share repurchases demonstrate resilience and strategic focus.
Challenges in the Life Science group highlight areas for improvement and strategic decision-making.

Bio-Rad Laboratories exceeds revenue targets in Q3 2024 earnings call

Bio-Rad Laboratories reported a strong Q3 performance with revenue surpassing targets driven by product mix and cost efficiencies.
While facing challenges in certain segments, opportunities lie in the expected return to growth in 2025 and the expansion of the Droplet Digital PCR franchise.
Maintained revenue guidance for 2024 with margin improvements and a focus on corporate transformations and acquisitions for future growth.
Analyst questions during the call covered a range of topics including margins, market dynamics, and product pricing.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, and test kits. The company was founded by David S. Schwartz and Alice N. Schwartz in 1952 and is headquartered in Hercules, CA.

Bio-Rad (BIO) reported earnings 30 days ago. What's next for the stock?

Why Is Bio-Rad (BIO) Down 13% Since Last Earnings Report?

Balchem

Reata Pharmaceuticals

Benjamin Graham, the father of value investing, recommended to stick to stocks that have a current ratio of more than 2 and more working capital than long-term debt.

3 High-Quality Picks for the Value Investor

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that Norman Schwartz, President and CEO; Andrew Last, Executive Vice President and COO; and Ilan Daskal, Executive Vice President and CFO will participate virtually in a Fireside Chat at Barclays Global Healthcare Conference on Tuesday, March 9, at 10:15 AM (PST). A link to the live webcast will be available in the Investo

Bio-Rad to Participate in Barclays Global Healthcare Conference 2021

Non-operating income not only overstates GAAP net income but could negatively impact Bio-Rad's ability to obtain additional financing.

Bio-Rad's Non-Operating Income Overstates GAAP Net Income

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that Norman Schwartz, President and CEO; Andrew Last, Executive Vice President and COO; and Ilan Daskal, Executive Vice President and CFO will participate virtually in a Fireside Chat at Citi's 2021 Healthcare Services, Medtech, Tools, & HCIT Virtual Conference on Wednesday, February 24, at 11:25 AM (PST). About Bio-Ra

Bio-Rad to Participate in Citi's 2021 Healthcare Services, Medtech, Tools, & HCIT Virtual Conference

Does Bio-Rad Laboratories (BIO) have what it takes to be a top stock pick for momentum investors? Let's find out.

What Makes Bio-Rad Laboratories (BIO) a Strong Momentum Stock: Buy Now?

Bio-Rad's (BIO) fourth-quarter 2020 results reflect strong performance by the Life Science segment, boosted by coronavirus-led increased testing demand.

Bio-Rad (BIO) Q4 Earnings Surpass Estimates, Margins Rise

Bio-Rad Laboratories, Inc. (BIO) CEO Norman Schwartz on Q4 2020 Results - Earnings Call Transcript

Bio-Rad (BIO) delivered earnings and revenue surprises of 29.35% and 15.85%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Bio-Rad Laboratories (BIO) Q4 Earnings and Revenues Surpass Estimates

Shares of Bio-Rad Laboratories (NYSE:BIO) moved higher by 2.0% in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 72.84% year over year to $4.01, which beat the estimate of $3.29.

Bio-Rad Laboratories: Q4 Earnings Insights

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the fourth quarter ended December 31, 2020. Fourth-quarter 2020 net sales were $789.8 million, an increase of 26.5 percent compared to $624.4 million reported for the fourth quarter of 2019. On a currency-neutral basis, quarterly sales increased 24.4 percent compared to the same period in 2019. Fourth

Bio-Rad Reports Fourth-Quarter and Full-Year 2020 Financial Results

Bio-Rad Laboratories (NYSE:BIO) unveils its next round of earnings this Thursday, February 11. Get prepared with Benzinga's ultimate preview for Bio-Rad Laboratories's Q4 earnings.

Earnings Preview: Bio-Rad Laboratories

Bio-Rad (BIO) Q4 earnings are expected to have benefited from strong sales, particularly within core PCR products, Droplet Digital PCR and Process Media.

Bio-Rad (BIO) to Report Q4 Earnings: What's in the Cards?

AGCO

Brandywine Realty

Brookfield Property REIT

Enphase Energy

Moderna

NortonLifeLock

NRG Energy

Peloton

Rockwell Automation

Tesla

Univar

Xerox

Zoom Video

These are the stocks with the best value, fastest growth, and most momentum for February.

Top Stocks for February 2021

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, will report financial results for the fourth quarter and full year 2020 on Thursday, February 11, 2021, following the close of the market. The company will discuss these results in a conference call scheduled for 3 PM Pacific Time (6 PM Eastern Time) that day. To listen, call 855-779-9068 within the U.S. or 631-485-4862 outside the U.S.,

Bio-Rad to Report Fourth-Quarter and Full-Year 2020 Financial Results Thursday, February 11, 2021

Biogen

CVS Health

Horizon Pharma

Insulet

QuidelOrtho Corp

Teladoc

These are the healthcare stocks with the best value, fastest growth, and most momentum for February 2021.

Top Healthcare Stocks for February 2021

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that Norman Schwartz, President and CEO; Andrew Last, Executive Vice President and COO; and Ilan Daskal, Executive Vice President and CFO will participate virtually in a Fireside Chat at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, at 1:30 PM (PST). A link to the live webcast is available in the

Bio-Rad to Participate in Fireside Chat at the 39th Annual J.P. Morgan Healthcare Conference on January 11

American Equity Investment Life

Cannae Hlds

FutureFuel

Ingles Markets

Renewable Energy Group

Unum

Worthington Industries

Huntsman

Piedmont Office Realty Trust

"Why do you like tobacco stocks so much?" my colleague asked our boss, David Dreman (Trades, Portfolio), about two decades ago.

Robot Portfolio Chugs Along, Seeking to Regain Past Glory

Acceleron Pharma

Health Care Select Sector SPDR Fund

These are the healthcare stocks with the best value, fastest growth, and most momentum for January 2021.

Top Healthcare Stocks for January 2021

Equity Commonwealth

First Foundation

LGI Homes

MSB Financial

MSG Networks

PennyMac Financial Services

Perhaps you've seen the Energizer Bunny in a battery commercial. It is "still going" long after you'd expect it to fade.

Can the Bunny Come Roaring Back?

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, announced today its outlook through 2023, which shows the company's commitment to continued organic growth, continued margin expansion, and its efforts on sustainability measures. “Since our last Investor Day in 2017, Bio-Rad has executed on the key metrics that were laid out and this has translated into delivering significant shareholder

Bio-Rad Provides Outlook Through 2023

These are the healthcare stocks with the best value, fastest growth, and most momentum for December 2020.

Top Healthcare Stocks for December 2020

Is (BIO) Outperforming Other Medical Stocks This Year?

Is BioRad Laboratories (BIO) Outperforming Other Medical Stocks This Year?

Plantronics

Shutterstock

Gentherm

Top Ranked Momentum Stocks to Buy for November 13th

Bank of New York Mellon

GCI Liberty

Value focused investors may want to consider the following stocks, since their share prices are trading at a discount to the intrinsic value calculated by GuruFocus' earnings-based discounted cash flow calculator.

News for Bio-Rad Laboratories Stock (BIO)